Loading: 100%
Alkermes PLC logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees 1,750 (as per Q1 2017)no data available
Sector Biotechnology, HealthcareBiotechnology, Healthcareno data available
Ticker ALKSno data available
Financial year endsFY ends End of Decemberno data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 174247525762
datesClosing price (adj.)
13.10.201750.29
11.10.201751.56
04.10.201751.87
27.09.201751.32
20.09.201750.66
13.09.201752.29
06.09.201749.81
30.08.201749.50
23.08.201750.21
16.08.201751.56
09.08.201752.38
02.08.201754.04
26.07.201757.57
19.07.201757.62
12.07.201757.87
05.07.201760.45
27.06.201757.12
20.06.201757.18
13.06.201758.61
06.06.201758.99
30.05.201757.70
23.05.201757.71
16.05.201760.47
09.05.201757.34
02.05.201758.51
25.04.201757.00
18.04.201755.90
11.04.201756.98
04.04.201758.75
28.03.201759.38
21.03.201757.36
14.03.201755.66
07.03.201758.80
28.02.201756.50
21.02.201754.19
14.02.201757.21
07.02.201754.77
31.01.201754.11
24.01.201755.71
17.01.201754.56
10.01.201758.49
03.01.201756.10
27.12.201656.77
19.12.201655.97
12.12.201655.14
05.12.201656.21
28.11.201657.77
21.11.201659.20
14.11.201659.02
07.11.201653.97
31.10.201650.41
24.10.201656.69
17.10.201642.37
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
50.29n/a
Market Capitalisation
in million USD
7,704n/a
Enterprise Value
in million USD
7,511n/a
Common Shares Outstanding
as per Apr 24, 2017
153,190,501n/a
Preferred Shares Outstanding
as per Apr 24, 2017
n/a
Average Basic Shares Outstanding
TTM
151,953,750n/a
Average Diluted Shares Outstanding
TTM
145,320,500n/a
Index Membership
n/a
Business Summary
Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.
no data available
Key Financials & Ratios (all figures TTM as per , million USD, full statements further below)
Profit & Loss
Revenues 0n/a
Gross Profit 0n/a
Operating Income 0n/a
EBITDA 0n/a
Net Profit 0n/a
Balance Sheet
Cash and Cash Equivalents 476n/a
Receivables 176n/a
Total Current Assets 759n/a
PP&E 265n/a
Total Assets 1,730n/a
Accounts Payable 205n/a
Current Debt 3n/a
Total Current Liabilities 211n/a
Long-Term Debt 280n/a
Total Liabilities 513n/a
Total Equity 1,217n/a
Cash Flow
Depreciation & Amortisation 95n/a
Change in Working Capital -17n/a
Operating Cash Flow -20n/a
Net Change in PP&E and Intangibles -41n/a
Investing Cash Flow 70n/a
Dividends Paid 0n/a
Financing Cash Flow -68n/a
Total Change in Cash -19n/a
Free Cash Flow 0n/a
Profitability Ratios
Gross Margin 0.0%n/a
Operating Margin 0.0%n/a
Net Profit Margin 0.0%n/a
Return on Equity 0.0%n/a
Return on Assets 0.0%n/a
Per Share Figures
Basic EPS n/a
Diluted EPS n/a
Sales per Share n/a
Book Value per Share 8.01n/a
FCF per Share n/a
Dividends per Share 0.00n/a
Price Multiples
Price to Earnings Ratio n/a
Price to Sales Ratio n/a
Price to Book Value 6.28n/a
Price to Free Cash Flow n/a
Valuation Metrics
EV/EBITDA n/a
EV/Sales n/a
Book to Market Value 0.16n/a
Other Ratios
Current Ratio 360.1%n/a
Liabilities to Equity Ratio 42.2%n/a
Debt to Assets Ratio 16.4%n/a
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Revenue
173
187
390
576
619
628
746
Sales & Services Revenue
0
0
0
0
0
0
0
Financing Revenue
0
0
0
0
0
0
0
Other Revenue
0
0
0
0
0
0
0
Cost of revenue
-49
-52
-128
-170
-176
-139
-132
Cost of Goods & Services
0
0
0
0
0
0
0
Cost of Financing Revenue
0
0
0
0
0
0
0
Cost of Other Revenue
0
0
0
0
0
0
0
Gross Profit
124
134
262
405
443
489
614
Other Operating Income
0
0
0
0
0
0
0
Operating Expenses
-172
-180
-305
-308
-530
-714
-822
Selling, General & Administrative
-77
-83
-138
-126
-200
-312
-374
Selling & Marketing
0
0
0
0
0
0
0
General & Administrative
0
0
0
0
0
0
0
Research & Development
-95
-97
-142
-140
-272
-344
-387
Depreciation & Amortization
0
0
-25
-42
-58
-58
-61
Provision For Doubtful Accounts
0
0
0
0
0
0
0
Other Operating Expense
0
0
0
0
0
0
0
Operating Income (Loss)
-48
-46
-42
97
-87
-224
-209
Non-Operating Income (Loss)
11
6
29
48
18
17
21
Interest Expense, net
11
6
30
50
15
17
19
Interest Expense
0
0
0
0
0
0
0
Interest Income
0
0
0
0
0
0
0
Other Investment Income (Loss)
0
0
0
0
0
0
0
Foreign Exchange Gain (Loss)
0
0
0
0
0
0
0
Income (Loss) from Affiliates
0
0
0
0
0
0
0
Other Non-Operating Income (Loss)
0
0
0
-2
2
0
2
Pretax Income (Loss), Adjusted
-37
-39
-13
146
-70
-208
-188
Abnormal Gains (Losses)
0
0
-46
-16
-87
-10
-8
Acquired In-Process R&D
0
0
0
0
0
0
0
Merger / Acquisition Expense
0
0
0
0
0
0
0
Abnormal Derivatives
0
0
0
0
0
0
0
Disposal of Assets
0
0
0
0
0
0
0
Early extinguishment of Debt
0
0
0
0
0
0
0
Asset Write-Down
0
0
0
0
0
0
0
Impairment of Goodwill & Intangibles
0
0
0
0
0
0
0
Sale of Business
0
0
0
0
0
0
0
Legal Settlement
0
0
0
0
0
0
0
Restructuring Charges
0
0
0
0
0
0
0
Sale of and Unrealized Investments
0
0
0
0
0
0
0
Insurance Settlement
0
0
0
0
0
0
0
Other Abnormal Items
0
0
0
0
0
0
0
Pretax Income (Loss)
-37
-39
-59
130
-156
-218
-195
Income Tax (Expense) Benefit, net
5
1
1
-10
-16
-3
6
Current Income Tax
0
0
0
0
0
0
0
Deferred Income Tax
0
0
0
0
0
0
0
Tax Allowance/Credit
0
0
0
0
0
0
0
Income (Loss) from Affiliates, net of taxes
0
0
0
0
0
0
0
Income (Loss) from Continuing Operations
-32
-38
-58
119
-172
-221
-189
Net Extraordinary Gains (Losses)
0
0
0
0
0
0
0
Discontinued Operations
0
0
0
0
0
0
0
XO & Accounting Charges & Other
0
0
0
0
0
0
0
Income (Loss) Including Minority Interest
-32
-38
-58
119
-172
-221
-189
Minority Interest
0
0
0
0
0
0
0
Net Income
-32
-38
-58
119
-172
-221
-189
Preferred Dividends
0
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
0
Net Income Available to Common Shareholders
-32
-38
-58
119
-172
-221
-189
Remarks
restated on May 18, 2012 n/a
calculated values,
restated on May 23, 2013 n/a
calculated values,
restated on May 23, 2013 n/a
calculated values,
restated on May 23, 2013 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Feb 17, 2017 n/a
calculated values,
restated on Feb 17, 2017 n/a
calculated values,
Balance SheetBS data quality: 93% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Assets
Cash, Cash Equivalents & Short Term Investments
n/a
201
190
362
631
535
497
Cash & Cash Equivalents
n/a
38
84
168
224
181
186
Short Term Investments
n/a
163
107
195
407
354
311
Accounts & Notes Receivable
n/a
23
96
134
152
155
191
Accounts Receivable, Net
n/a
23
96
134
152
155
191
Notes Receivable, Net
n/a
0
0
0
0
0
0
Unbilled Revenues
n/a
0
0
0
0
0
0
Inventories
n/a
20
40
46
51
38
63
Raw Materials
n/a
0
0
0
0
0
0
Work In Process
n/a
0
0
0
0
0
0
Finished Goods
n/a
0
0
0
0
0
0
Other Inventory
n/a
0
0
0
0
0
0
Other Short Term Assets
n/a
8
13
28
43
26
39
Prepaid Expenses
n/a
8
13
15
29
26
39
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
Assets Held-for-Sale
n/a
0
0
0
0
0
0
Deferred Tax Assets
n/a
0
0
13
13
0
0
Income Taxes Receivable
n/a
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
Miscellaneous Short Term Assets
n/a
0
0
0
0
0
0
Total Current Assets
n/a
253
339
570
877
755
791
Property, Plant & Equipment, Net
n/a
95
303
274
266
255
265
Property, Plant & Equipment
n/a
0
0
0
0
0
0
Accumulated Depreciation
n/a
0
0
0
0
0
0
Long Term Investments & Receivables
n/a
93
56
88
170
264
122
Long Term Investments
n/a
0
0
0
0
0
0
Long Term Marketable Securities
n/a
0
0
0
0
0
0
Long Term Receivables
n/a
0
0
0
0
0
0
Other Long Term Assets
n/a
11
737
645
606
582
549
Intangible Assets
n/a
0
618
538
479
379
318
Goodwill
n/a
0
93
93
94
93
93
Other Intangible Assets
n/a
0
0
0
0
0
0
Prepaid Expense
n/a
0
0
0
0
0
0
Deferred Tax Assets
n/a
0
0
0
8
41
48
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
Prepaid Pension Costs
n/a
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
Investments in Affiliates
n/a
0
0
0
0
0
0
Miscellaneous Long Term Assets
n/a
11
27
15
24
69
90
Total Noncurrent Assets
n/a
199
1,096
1,007
1,042
1,101
936
Total Assets
n/a
452
1,435
1,578
1,919
1,856
1,726
Liabilities and owners' equity
Payables & Accruals
n/a
45 44934000
79 79154000
91 91173000
121 121258000
169 168735000
207 207055000
Accounts Payable
n/a
45 44934000
79 79154000
91 91173000
121 121258000
169 168735000
207 207055000
Accrued Taxes
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Interest & Dividends Payable
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Payables & Accruals
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Short Term Debt
n/a
0 0
3 3100000
7 6750000
7 6750000
66 65737000
3 3000000
Short Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Short Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Current Portion of Long Term Debt
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Short Term Liabilities
n/a
3 3123000
7 6910000
3 2974000
3 2574000
2 1735000
2 1938000
Deferred Revenue
n/a
3 3123000
7 6910000
3 2974000
3 2574000
2 1735000
2 1938000
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Short Term Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Total Current Liabilities
n/a
48 48057000
89 89164000
101 100897000
131 130582000
236 236207000
212 211993000
Long Term Debt
n/a
0 0
441 441360000
358 357543000
349 349006000
284 284207000
281 280666000
Long Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Long Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Long Term Liabilities
n/a
12 12373000
51 50841000
54 53962000
43 42633000
21 21055000
24 24283000
Accrued Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Pension Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Pensions
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Post-Retirement Benefits
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Compensation
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Revenue
n/a
5 4837000
8 7578000
12 12213000
12 11801000
8 7975000
7 7122000
Deferred Tax Liabilities
n/a
0 0
35 34512000
29 29169000
19 18918000
0 0
0 0
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Long Term Liabilities
n/a
8 7536000
9 8751000
13 12580000
12 11914000
13 13080000
17 17161000
Total Noncurrent Liabilities
n/a
12 12373000
492 492201000
412 411505000
392 391639000
305 305262000
305 304949000
Total Liabilities
n/a
60 60430000
581 581365000
512 512402000
522 522221000
541 541469000
517 516942000
Preferred Equity
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Share Capital & Additional Paid-In Capital
n/a
937 937350000
1,382 1382042000
1,555 1554719000
1,944 1944360000
2,116 2116229000
2,233 2233336000
Common Stock
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Additional Paid in Capital
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Share Capital
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Treasury Stock
n/a
-131 -131095000
-1 -571000
-18 -17833000
-32 -32052000
-59 -58661000
-73 -72639000
Retained Earnings
n/a
-411 -411228000
-525 -524906000
-482 -482274000
-512 -512335000
-739 -739498000
-948 -947942000
Other Equity
n/a
-3 -3013000
-3 -2713000
11 10574000
-3 -3136000
-4 -3795000
-3 -3274000
Equity Before Minority Interest
n/a
392 392014000
854 853852000
1,065 1065186000
1,397 1396837000
1,314 1314275000
1,209 1209481000
Minority Interest
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Total Equity
n/a
392 392014000
854 853852000
1,065 1065186000
1,397 1396837000
1,314 1314275000
1,209 1209481000
Total Liabilities & Equity
n/a
452 452444000
1,435 1435217000
1,578 1577588000
1,919 1919058000
1,856 1855744000
1,726 1726423000
Remarks restated on n/a restated on May 18, 2012 n/a restated on May 23, 2013 n/a restated on Feb 24, 2015 n/a restated on Feb 25, 2016 n/a restated on Feb 17, 2017 n/a restated on Apr 27, 2017 n/a
Cash Flow StatementCF data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Net Income/Starting Line
-40
-46
-114
25
-30
-227
-208
Net Income
0
0
0
0
0
0
0
Net Income From Discontinued Operations
0
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
0
Depreciation & Amortization
25
9
48
74
98
86
94
Non-Cash Items
12
14
56
44
-62
21
75
Stock-Based Compensation
0
0
0
0
0
0
0
Deferred Income Taxes
0
0
0
0
0
0
0
Other Non-Cash Adjustments
0
0
0
0
0
0
0
Change in Working Capital
-9
17
8
-16
5
81
-24
(Increase) Decrease in Accounts Receivable
0
0
0
0
0
0
0
(Increase) Decrease in Inventories
0
0
0
0
0
0
0
Increase (Decrease) in Accounts Payable
0
0
0
0
0
0
0
Increase (Decrease) in Other
0
0
0
0
0
0
0
Net Cash From Discontinued Operations (operating)
0
0
0
0
0
0
0
Cash from Operating Activities
-12
-6
-2
127
11
-40
-64
Change in Fixed Assets & Intangibles
-16
-9
-17
-22
11
-52
-43
Disposition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
Disposition of Fixed Assets
0
0
0
0
0
0
0
Disposition of Intangible Assets
0
0
0
0
0
0
0
Acquisition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
Purchase of Fixed Assets
0
0
0
0
0
0
0
Acquisition of Intangible Assets
0
0
0
0
0
0
0
Other Change in Fixed Assets & Intangibles
0
0
0
0
0
0
0
Net Change in Long Term Investment
52
15
95
-45
-301
-41
186
Decrease in Long Term Investment
0
0
0
0
0
0
0
Increase in Long Term Investment
0
0
0
0
0
0
0
Net Cash From Acquisitions & Divestitures
-8
-1
-495
-1
27
50
-15
Net Cash from Divestitures
0
0
0
0
0
0
0
Cash for Acqusition of Subsidiaries
0
0
0
0
0
0
0
Cash for Joint Ventures
0
0
0
0
0
0
0
Net Cash from Other Acquisitions
0
0
0
0
0
0
0
Other Investing Activities
0
0
0
0
0
0
0
Net Cash From Discontinued Operations (investing)
0
0
0
0
0
0
0
Cash from Investing Activities
28
6
-417
-68
-263
-43
127
Dividends Paid
0
0
0
0
0
0
0
Cash From (Repayment of) Debt
0
0
443
-83
-7
-7
-69
Cash From (Repayment of) Short Term Debt, net
0
0
0
0
0
0
0
Cash From (Repayment of) Long Term Debt, net
0
0
0
0
0
0
0
Repayments of Long Term Debt
0
0
0
0
0
0
0
Cash From Long Term Debt
0
0
0
0
0
0
0
Cash From (Repurchase of) Equity
0
6
21
34
296
45
20
Increase in Capital Stock
3
6
21
34
296
45
20
Decrease in Capital Stock
-3
0
0
0
0
0
0
Other Financing Activities
-23
-47
1
4
20
3
-9
Net Cash From Discontinued Operations (financing)
0
0
0
0
0
0
0
Cash from Financing Activities
-23
-41
465
-45
309
41
-58
Net Cash Before Disc. Operations and FX
-8
-41
45
13
57
-43
5
Change in Cash from Disc. Operations and Other
0
0
0
0
0
0
0
Net Cash Before FX
-8
-41
45
13
57
-43
5
Effect of Foreign Exchange Rates
0
0
0
0
0
0
0
Net Changes in Cash
-8
-41
45
13
57
-43
5
Remarks
restated on May 18, 2012 n/a
calculated values,
restated on May 23, 2013 n/a
calculated values,
restated on May 23, 2013 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Feb 17, 2017 n/a
calculated values,
restated on Feb 17, 2017 n/a
calculated values,
restated on Feb 17, 2017 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo